Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBISTRAT: AmBisome + Caspofungin vs High-Dose AmBisome in Invasive Aspergillosis
NCT00334412Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2004
- Modality
- Cyclic Peptides, Lipid-based Nanoparticles, Antimicrobial Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of liposomal amphotericin b, caspofungin in invasive aspergillosis (IA), sponsored by Gilead Sciences. Started Mar 2004; status: completed.
02
Drugs
liposomal amphotericin bcaspofungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT00334412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334412.